Effect on absorption and oxidative stress of different oral Coenzyme Q 10 dosages and intake strategy in healthy men

BioFactors

Volumn 25, Issue 1-4, 2005, Pages 219-224

  Singh, R B ^a,d   Niaz, M A ^a   Kumar, Adarsh ^a   Sindberg, C D ^b   Moesgaard, S ^b   Littarru, G P ^c  

^a HALBERG HOSPITAL AND RESEARCH INSTITUTE   (India)

^b Pharma Nord ApS   (Denmark)

^c Biochemistry Institute   (Italy)

^d Halberg Hospital and Research Institute ^*  (India)

Author keywords

Antioxidant; Dose strategy; Oxidative stress; Q10 formulations; Uptake

Indexed keywords

ANTIAMEBIC AGENT; MALONALDEHYDE; MYOQINON; PLACEBO; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UBIDECARENONE;

ADULT; BIOEQUIVALENCE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG RESPONSE; GASTROINTESTINAL ABSORPTION; HUMAN; MONITORING; NORMAL HUMAN; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION;

EID: 33746076342     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520250127     Document Type: Conference Paper

References (19)

1. 10 and adverse effects of statins, J Nutr Environ Med 14 (2004), 17-28.
2. 10) in Amyotrophic Lateral Sclerosis, Motor Neuron Disord (Suppl 3) (2000), 119.
3. 10 and remacemide in Huntington's disease, Neurology 57 (2001), 397-404.
4. 10) in healthy subjects: A double-blind, randomized, placebo-controlled trial. Regul Toxicol Pharmacol (Jan 20 2006), in press.
5. 10 supplementation on the oxidation resistance of human VLDL+LDL fractions: absorptions and antioxidative properties of oil and granule based preparations, Free Rad Biol Med 22 (1997), 1195-1202.
6. 10, New York, Elsevier Science Publishers, 1983, pp. 131-142.
7. 10 deficiency, Neurology 60 (2003), 1206-1208.
8. 10 in clinical cardiology:a longterm study, Mol Aspects of Med 15(Supple) (1994), 165-175.
9. 10 administration increases brain mitochondrial concentration and exerts neuroprotective effects, Proc Natl Acad Sci USA 95 (1998), 8892-8897.
10. 10 from over the counter supplements, Nutr Res 22 (2002), 919-929.
11. 10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio" - a multinational trial, Biofactors 18 (2003), 79-89.
12. 10 level in the blood of patients at risk for cardiovascular disease, Arch Neurol 61 (2004), 889-892.
13. 10 in early Parkinson disease, Arch Neurol 59 (2002), 1541-1550.
14. 10 in new indications with antioxidant deficiency, J Nutr Environ Med 9 (1999), 223-228.
15. 10 in patients with end stage renal failure, J Nutr Environ Med 13 (2003), 13-23.
16. R.B. Singh, D. Pella, J.P. Sharma et al., Increased concentrations of lipoprotein(a), circadian rhythms and metabolic reactions, evoked by acute myocardial infarction, associated with acute reactions in relation to large breakfast, Biomed Pharmacother 58(Supple) (2004), 116-122.
17. 10 in the diet-daily intake, and relative bioavailability, Molec Aspects Med 18(Suppl) (1997), 251-254.
18. 10 formulations in healthy volunteers, Mol Aspects of Med 15(Supple) (1994), 273-280.
19. 10 for two months in a randomized controlled study.